Cargando…
To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia
OBJECTIVE: Primary objective was to compare the effects of atorvastatin 40 mg vs 80 mg on LDL-C in Indian patients with atherosclerotic dyslipidemia. Secondary objectives were to compare the effects of atorvastatin 40 mg vs 80 mg on HDL-C and triglycerides and also comparing of side effects (myopath...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310693/ https://www.ncbi.nlm.nih.gov/pubmed/30595326 http://dx.doi.org/10.1016/j.ihj.2018.01.034 |
_version_ | 1783383475172147200 |
---|---|
author | Agrawal, Deepak Manchanda, S.C. Sawhney, J.P.S. Kandpal, Bhuwanesh Jain, Rajneesh Mehta, Ashwani Mohanty, Arun Passey, Rajiv Makhija, Aman Sharma, Manish Kr. |
author_facet | Agrawal, Deepak Manchanda, S.C. Sawhney, J.P.S. Kandpal, Bhuwanesh Jain, Rajneesh Mehta, Ashwani Mohanty, Arun Passey, Rajiv Makhija, Aman Sharma, Manish Kr. |
author_sort | Agrawal, Deepak |
collection | PubMed |
description | OBJECTIVE: Primary objective was to compare the effects of atorvastatin 40 mg vs 80 mg on LDL-C in Indian patients with atherosclerotic dyslipidemia. Secondary objectives were to compare the effects of atorvastatin 40 mg vs 80 mg on HDL-C and triglycerides and also comparing of side effects (myopathy, hepatotoxicity and new onset diabetes mellitus) of both doses. METHOD: This Study is A Prospective, randomized, open-label, comparative study. This study was conducted on 240 patients of dyslipidemia (as per ACC/AHA 2013 lipid guidelines) attending the OPD/wards/CCU of department of cardiology, Sir Ganga Ram Hospital. They were randomly divided into 2 groups of 120 each. Group A consisted patients who received Atorvastatin 40 mg daily and Group B Atorvastatin 80 mg daily. The follow up period was 6 months. RESULTS: At 3 and 6 month follow up, Atorvastatin 40 mg leads to mean LDL cholesterol reduction of 47.18 ± 20.81 & 50.03 ± 18.06 respectively. While Atorvastatin 80 mg results in LDL reduction as 50.11 ± 15.85 & 52.30 ± 13.72. The comparison between two doses revealed a non-significant difference (p = .118 & p = .149 respectively). At 6 months of follow up, few patients reported myalgia (2 in group A and 7 in Group B). The difference between groups was significant (p = .045). Although none of our patient had significant elevation of CPK. CONCLUSION: This study concluded that both doses of atorvastatin (40 & 80 mg) are equally efficacious in improving dyslipidemia but higher dose leads to more incidence of myalgia. |
format | Online Article Text |
id | pubmed-6310693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63106932019-12-01 To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia Agrawal, Deepak Manchanda, S.C. Sawhney, J.P.S. Kandpal, Bhuwanesh Jain, Rajneesh Mehta, Ashwani Mohanty, Arun Passey, Rajiv Makhija, Aman Sharma, Manish Kr. Indian Heart J Clinical and Preventive Cardiology OBJECTIVE: Primary objective was to compare the effects of atorvastatin 40 mg vs 80 mg on LDL-C in Indian patients with atherosclerotic dyslipidemia. Secondary objectives were to compare the effects of atorvastatin 40 mg vs 80 mg on HDL-C and triglycerides and also comparing of side effects (myopathy, hepatotoxicity and new onset diabetes mellitus) of both doses. METHOD: This Study is A Prospective, randomized, open-label, comparative study. This study was conducted on 240 patients of dyslipidemia (as per ACC/AHA 2013 lipid guidelines) attending the OPD/wards/CCU of department of cardiology, Sir Ganga Ram Hospital. They were randomly divided into 2 groups of 120 each. Group A consisted patients who received Atorvastatin 40 mg daily and Group B Atorvastatin 80 mg daily. The follow up period was 6 months. RESULTS: At 3 and 6 month follow up, Atorvastatin 40 mg leads to mean LDL cholesterol reduction of 47.18 ± 20.81 & 50.03 ± 18.06 respectively. While Atorvastatin 80 mg results in LDL reduction as 50.11 ± 15.85 & 52.30 ± 13.72. The comparison between two doses revealed a non-significant difference (p = .118 & p = .149 respectively). At 6 months of follow up, few patients reported myalgia (2 in group A and 7 in Group B). The difference between groups was significant (p = .045). Although none of our patient had significant elevation of CPK. CONCLUSION: This study concluded that both doses of atorvastatin (40 & 80 mg) are equally efficacious in improving dyslipidemia but higher dose leads to more incidence of myalgia. Elsevier 2018-12 2018-01-31 /pmc/articles/PMC6310693/ /pubmed/30595326 http://dx.doi.org/10.1016/j.ihj.2018.01.034 Text en © 2018 Published by Elsevier B.V. on behalf of Cardiological Society of India. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical and Preventive Cardiology Agrawal, Deepak Manchanda, S.C. Sawhney, J.P.S. Kandpal, Bhuwanesh Jain, Rajneesh Mehta, Ashwani Mohanty, Arun Passey, Rajiv Makhija, Aman Sharma, Manish Kr. To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia |
title | To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia |
title_full | To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia |
title_fullStr | To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia |
title_full_unstemmed | To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia |
title_short | To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia |
title_sort | to study the effect of high dose atorvastatin 40 mg versus 80 mg in patients with dyslipidemia |
topic | Clinical and Preventive Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310693/ https://www.ncbi.nlm.nih.gov/pubmed/30595326 http://dx.doi.org/10.1016/j.ihj.2018.01.034 |
work_keys_str_mv | AT agrawaldeepak tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT manchandasc tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT sawhneyjps tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT kandpalbhuwanesh tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT jainrajneesh tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT mehtaashwani tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT mohantyarun tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT passeyrajiv tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT makhijaaman tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia AT sharmamanishkr tostudytheeffectofhighdoseatorvastatin40mgversus80mginpatientswithdyslipidemia |